Peptron shares drop 25% as Eli Lilly evaluation ends
Peptron said its SmartDepot technology evaluation with Eli Lilly concluded without a commercialization contract; follow-up cooperation terms remain undisclosed.
Peptron disclosed on its website that its technology evaluation period with Eli Lilly for the SmartDepot platform ended without a commercialization contract, according to inews24.com. Shares of the company fell 25.11% to 97,800 won in early trading on the Korea Exchange.
Peptron stated that the end of the technology evaluation period means the joint research and evaluation procedures under the evaluation agreement were completed. The company said the conclusion of the evaluation does not mean the end of possible commercialization cooperation between the two companies.
Peptron added that it cannot currently disclose the specific method and timing of any follow-up cooperation.
Background
In 2024, Peptron signed a non-exclusive technology evaluation agreement with Eli Lilly to apply its long-acting drug delivery platform SmartDepot to Lilly's peptide drugs. Peptron shares fell 25.80% in the aftermarket the previous day.
よくある質問
What happened to Peptron shares after the Eli Lilly evaluation ended?
Peptron shares fell 25.11% to 97,800 won in early trading on the Korea Exchange.
Does the end of the evaluation mean Peptron and Eli Lilly will stop working together?
Peptron said the end of the evaluation does not mean the end of possible commercialization cooperation between the two companies.
When did Peptron sign the evaluation agreement with Eli Lilly?
In 2024, Peptron signed a non-exclusive technology evaluation agreement with Eli Lilly for the SmartDepot platform.